Background The prognosis of people with metastatic cutaneous melanoma, a skin cancer, is
generally poor. Recently, new classes of drugs (eg immune checkpoint inhibitors and small …

We undertook a systematic review of 41 randomised studies in disseminated melanoma,
identified by a comprehensive search. We aimed to investigate rates of response to various …

This review assessed the effects of biochemotherapy for treating metastatic melanoma as
compared to chemotherapy. It concluded that biochemotherapy clearly improved response …

BACKGROUND: Advanced melanomas (non-resectable Stage-III/IV) are fatal, with few
effective treatments. It remains unclear if other drugs offer improvements over the standard …

Background Malignant melanoma, one of the most aggressive of all skin cancers, is
increasing in incidence throughout the world. Surgery remains the cornerstone of curative …

It is currently unclear whether any combination therapy for the treatment of metastatic
melanoma is superior to standard single-agent dacarbazine (DTIC) in terms of tumour …

Purpose Temozolomide (TMZ) has shown efficacy in metastatic melanoma equal to that of
dacarbazine (DTIC), the standard chemotherapeutic agent for melanoma. As the …

Aims In the metastatic stage, malignant melanoma is resistant to systemic treatment and
carries a poor prognosis. A critical, evidence‐based analysis of standard approaches based …

The effect of interferon-alpha (IFN-[alpha]) as single agent or in combination in the treatment
of metastatic malignant melanoma (MM) or of advanced renal cell carcinoma (RCC) has …

Considering that well-defined and comprehensive immunological monitoring is the basis for
the evaluation of the obtained immunmodulatory effects, we evaluated NK-cell activity, the …